title: Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class.
abstract: We have studied transmitted drug resistance (TDR) in 1.864 antiretroviral-naïve patients entering CoRIS (Spain) during 2007-2010. An overall 8.58% TDR was observed (3.92%, nucleoside reverse transcriptase inhibitors (NRTIs); 3.86%, non-nucleoside reverse transcriptase inhibitors (NNRTIs); 2.31%, protease inhibitors), with a significant decreasing trend over time for NNRTIs (5.53%, 2007; 2.45%, 2010; p for trend = 0.044). Non-B subtype prevalence was 15.93%, with a significant increase (11.95%, 2007; 18.14%, 2010; p for trend = 0.018), mainly related to immigration. Having no formal education increased the risk of TDR to NNRTIs (OR, 7.26), and carrying a non-B subtype reduced the risk of TDR to NRTIs (OR, 0.27). These findings may have important implications for treatment guidelines and laboratory testing recommendations.
authors.affiliation: Instutito de Salud Carlos III, Madrid, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Monge
authors.forename: V
authors.initials: V
authors.lastname: Guillot
authors.forename: M
authors.initials: M
authors.lastname: Alvarez
authors.forename: A
authors.initials: A
authors.lastname: Peña
authors.forename: P
authors.initials: P
authors.lastname: Viciana
authors.forename: S
authors.initials: S
authors.lastname: García-Bujalance
authors.forename: M J
authors.initials: MJ
authors.lastname: Pérez Elias
authors.forename: J A
authors.initials: JA
authors.lastname: Iribarren
authors.forename: F
authors.initials: F
authors.lastname: Gutiérrez
authors.forename: M
authors.initials: M
authors.lastname: Itziar Casado
authors.forename: F
authors.initials: F
authors.lastname: Garcia
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D005260:Female; D005838:Genotype; D006678:HIV / Q000187:drug effects* / Q000302:isolation & purification; D015658:HIV Infections / Q000453:epidemiology / Q000635:transmission* / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D006801:Humans; D008297:Male; D020125:Mutation, Missense; D009705:Nucleosides / Q000008:administration & dosage / Q000494:pharmacology; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D013030:Spain / Q000453:epidemiology
chemical_list: D044966:Anti-Retroviral Agents; D009705:Nucleosides; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase